clinical trial · NCT07582133
A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
Chengdu Suncadia Medicine Co., Ltd.·phase2·recruiting·n = 380
Primary IgA NephropathyHRS-5965 Capsules
brief summary
This study aims to evaluate the long-term safety of HRS-5965 capsules in patients with primary IgA nephropathy, and also to assess its efficacy in reducing 24-hour urinary protein and delaying the decline in eGFR in these patients.
started
Jul 6, 2026
primary completion
Jul 1, 2029
completion
Nov 1, 2029
last updated
Jul 22, 2026
official title
A Multicenter, Open-label Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 Capsules in Patients With Primary IgA Nephropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol